Approval · Notice of Compliance 633 · 2003
LOVENOX: Notice of Compliance 633
Issued February 28, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 633
- Date
- February 28, 2003
- Company
- Aventis Pharma Inc.Laval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revisions to the product monograph including reduced dosage regimen for patients with severe renal impairment
- Therapeutic class
- Anticoagulant, antithrombotic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LOVENOX | Not yet assigned | — |
| LOVENOX HP | Not yet assigned | — |
Medicinal ingredients
- ENOXAPARIN SODIUM 100 MG per ML
- ENOXAPARIN SODIUM 150 MG per ML